GlassScriptPhysician profile
Emmanuel Quaye
NPI 1043249949
$1,983.12
in general payments reported to CMS, 2019-2025
24 companies · $314 in 2025
The $314 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $68.23 · 2020: $127 · 2021: $24.70 · 2022: $209 · 2023: $116 · 2024: $1,124 · 2025: $314.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,554.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,553.67 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $407.44 | 2020-2025 | Farxiga, Breztri, Airsupra |
| Abbvie INC. | $284.12 | 2022-2025 | |
| Novo Nordisk INC | $218.04 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Lilly USA, LLC | $199.87 | 2023-2024 | Mounjaro, Zepbound, Jardiance |
| Bayer Healthcare Pharmaceuticals INC. | $163.16 | 2024 | |
| Amgen INC. | $129.74 | 2024-2025 | Repatha, Otezla, Otezla |
| Forte Bio-Pharma LLC | $126.08 | 2019-2020 | |
| Novartis Pharmaceuticals Corporation | $77.57 | 2019-2024 | |
| Astellas Pharma US INC | $46.17 | 2024 | Veozah |
| Exact Sciences Corporation | $45.22 | 2023-2024 | Cologuard Collection Kit |
| Sanofi-Aventis U.S. LLC | $40.76 | 2019-2022 | |
| Bard Peripheral Vascular, INC. | $38.64 | 2022 | |
| Merck Sharp & Dohme LLC | $26.54 | 2022-2024 | Vaxneuvance, M-M-R II, Vaxelis |
| Ironwood Pharmaceuticals, INC | $21.09 | 2024 | |
| Cranial Technologies, INC | $19.92 | 2024 | Doc Band |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Hikma Pharmaceuticals USA | $18.99 | 2024 | Ryaltris |
| Glaxosmithkline, LLC. | $18.69 | 2024 | Trelegy Ellipta |
| Xeris Pharmaceuticals, INC. | $18.33 | 2022 | |
| Dexcom, INC. | $15.90 | 2024 | Dexcom G6 Transmitter |
| Boehringer Ingelheim Pharmaceuticals, INC. | $15.88 | 2024 | Jardiance |
| Abbott Laboratories | $15.19 | 2022 | |
| Avanir Pharmaceuticals, INC. | $12.74 | 2021 | |
| Corcept Therapeutics | $11.96 | 2021 | |
| Vyera Pharmaceuticals, LLC | $11.08 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Emmanuel Quaye listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.